Literature DB >> 33837438

Sublingual immunotherapy for 4 years increased the number of Foxp3+ Treg cells, which correlated with clinical effects.

Tetsuya Terada1, Masaya Matsuda2, Miki Inaba2, Junpei Hamaguchi2, Naoki Takemoto2, Yusuke Kikuoka1, Yuko Inaka1, Harumi Sakae2, Kennosuke Hashimoto2, Hayato Shimora2, Kazuyuki Kitatani2, Ryo Kawata1, Takeshi Nabe3.   

Abstract

OBJECTIVE: At least 3 years of sublingual immunotherapy (SLIT) is required to achieve long-term clinical tolerance for allergens. However, immunological changes with more than 3 years of SLIT have not yet been elucidated in detail. The present study investigated whether the numbers of regulatory T (Treg) cells and regulatory B (Breg) cells increased with 4 years of SLIT and if these increases correlated with clinical effects for pollinosis.
METHODS: Seven Japanese cedar pollinosis patients received SLIT in 2014 or 2015 and continued treatment until May 2019. In May 2017 and May 2019, peripheral blood mononuclear cells (PBMCs) were collected from the patients, and analyzed by flow cytometer.
RESULTS: (1) The visual analogue scale (VAS) was significantly higher in 2019 than in 2017. (2) The percentages of Foxp3+ Treg cells, type 1 regulatory T (Tr1) cells, and Breg cells in PBMCs were significantly higher in 2019 than in 2017. (3) The percentage of Foxp3+ Treg cells in PBMCs positively correlated with VAS, whereas those of Tr1 cells and Breg cells did not.
CONCLUSIONS: These results suggest that 4 years of SLIT is needed to achieve sustained increases in Foxp3+ Treg cells, which are closely associated with the efficacy of SLIT.

Entities:  

Keywords:  Allergic rhinitis; Immunotherapy; Japanese cedar pollinosis; Regulatory B cells; Regulatory T cells

Year:  2021        PMID: 33837438     DOI: 10.1007/s00011-021-01460-3

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  30 in total

1.  Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey.

Authors:  Samuel J Arbes; Peter J Gergen; Leslie Elliott; Darryl C Zeldin
Journal:  J Allergy Clin Immunol       Date:  2005-08       Impact factor: 10.793

2.  Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.

Authors:  Guy W Scadding; Moises A Calderon; Mohamed H Shamji; Aarif O Eifan; Martin Penagos; Florentina Dumitru; Michelle L Sever; Henry T Bahnson; Kaitie Lawson; Kristina M Harris; Audrey G Plough; Joy Laurienzo Panza; Tielin Qin; Noha Lim; Nadia K Tchao; Alkis Togias; Stephen R Durham
Journal:  JAMA       Date:  2017-02-14       Impact factor: 56.272

3.  Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled study.

Authors:  Hideyuki Yamamoto; Takechiyo Yamada; Seita Kubo; Yoko Osawa; Yuichi Kimura; Myonmi Oh; Dai Susuki; Tetsuji Takabayashi; Masayuki Okamoto; Shigeharu Fujieda
Journal:  Allergy Asthma Proc       Date:  2010 Jul-Aug       Impact factor: 2.587

4.  A randomized control trail of stepwise treatment with fluticasone propionate nasal spray and fexofenadine hydrochloride tablet for seasonal allergic rhinitis.

Authors:  Goro Takahashi; Zensei Matsuzaki; Atsushi Okamoto; Eiko Ito; Tomokazu Matsuoka; Takeo Nakayama; Keisuke Masuyama
Journal:  Allergol Int       Date:  2011-12-25       Impact factor: 5.836

Review 5.  International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics.

Authors:  Marek Jutel; Ioana Agache; Sergio Bonini; A Wesley Burks; Moises Calderon; Walter Canonica; Linda Cox; Pascal Demoly; Antony J Frew; Robyn O'Hehir; Jörg Kleine-Tebbe; Antonella Muraro; Gideon Lack; Désirée Larenas; Michael Levin; Bryan L Martin; Harald Nelson; Ruby Pawankar; Oliver Pfaar; Ronald van Ree; Hugh Sampson; James L Sublett; Kazunari Sugita; George Du Toit; Thomas Werfel; Roy Gerth van Wijk; Luo Zhang; Mübeccel Akdis; Cezmi A Akdis
Journal:  J Allergy Clin Immunol       Date:  2016-02       Impact factor: 10.793

6.  Delay of onset of symptoms of Japanese cedar pollinosis by treatment with a leukotriene receptor antagonist.

Authors:  Minoru Gotoh; Hidenori Suzuki; Kimihiro Okubo
Journal:  Allergol Int       Date:  2011-07-25       Impact factor: 5.836

Review 7.  Present state of Japanese cedar pollinosis: the national affliction.

Authors:  Takechiyo Yamada; Hirohisa Saito; Shigeharu Fujieda
Journal:  J Allergy Clin Immunol       Date:  2013-12-19       Impact factor: 10.793

8.  Immunological effects of sublingual immunotherapy with Japanese cedar pollen extract in patients with combined Japanese cedar and Japanese cypress pollinosis.

Authors:  Hirotaka Kikuoka; Hideaki Kouzaki; Koji Matsumoto; Hiroyuki Arai; Sayuri Yamamoto; Ichiro Tojima; Shino Shimizu; Hiromi Miyashita; Yukiko Ogawa; Toshihiro Osada; Mitsuhiro Okano; Atsushi Yuta; Takeshi Shimizu
Journal:  Clin Immunol       Date:  2019-11-16       Impact factor: 3.969

Review 9.  Recent developments and highlights in immune monitoring of allergen immunotherapy.

Authors:  Menno C van Zelm; Craig I McKenzie; Nirupama Varese; Jennifer M Rolland; Robyn E O'Hehir
Journal:  Allergy       Date:  2019-11-08       Impact factor: 13.146

Review 10.  International consensus on allergy immunotherapy.

Authors:  Marek Jutel; Ioana Agache; Sergio Bonini; A Wesley Burks; Moises Calderon; Walter Canonica; Linda Cox; Pascal Demoly; Antony J Frew; Robin O'Hehir; Jörg Kleine-Tebbe; Antonella Muraro; Gideon Lack; Désirée Larenas; Michael Levin; Harald Nelson; Ruby Pawankar; Oliver Pfaar; Ronald van Ree; Hugh Sampson; Alexandra F Santos; George Du Toit; Thomas Werfel; Roy Gerth van Wijk; Luo Zhang; Cezmi A Akdis
Journal:  J Allergy Clin Immunol       Date:  2015-07-07       Impact factor: 10.793

View more
  2 in total

1.  Effectiveness and safety of allergen immunotherapy in patients with allergic rhinitis complicated by rheumatic autoimmune diseases: a case series study.

Authors:  Kazuki Fujioka; Akiko Kasahara; Takashi Kida; Wataru Fujii; Takahiro Seno; Makoto Wada; Masataka Kohno; Yutaka Kawahito
Journal:  Allergy Asthma Clin Immunol       Date:  2022-07-11       Impact factor: 3.373

Review 2.  Roles of type 1 regulatory T (Tr1) cells in allergen-specific immunotherapy.

Authors:  Masaya Matsuda; Tetsuya Terada; Kazuyuki Kitatani; Ryo Kawata; Takeshi Nabe
Journal:  Front Allergy       Date:  2022-08-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.